Compare GSBD & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | GSBD | YDES |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.2M |
| IPO Year | 2013 | N/A |
| Metric | GSBD | YDES |
|---|---|---|
| Price | $9.06 | $7.56 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 11.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 14.46% | N/A |
| EPS Growth | ★ 87.27 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.81 | $7.51 |
| 52 Week High | $12.43 | $25.00 |
| Indicator | GSBD | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 29.22 |
| Support Level | $8.94 | N/A |
| Resistance Level | $9.53 | $13.19 |
| Average True Range (ATR) | 0.23 | 0.52 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 40.44 | 0.00 |
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.